Episode #192. What It Takes To Turn Nature-Inspired Molecules Into Real Medicines, with Caitlyn Krebs, Co-founder & CEO of Nalu Bio

The endocannabinoid system could become a platform as consequential as GLP-1s, starting with non-addictive, disease-modifying therapies for women’s health and chronic pain.

In this episode, Caitlyn Krebs discusses how generative AI is accelerating the design of oral small molecules that target CB1 and CB2 receptors for pain, inflammation, and endometriosis. She breaks down why today’s endometriosis treatments often force patients into intolerable tradeoffs, how AI helps optimize and prioritize better drug candidates than naturally occurring cannabinoids, and what “preclinical to IND” progress looks like on the path to human studies.

Tune in and learn how AI and the endocannabinoid system could reshape pain care and women’s health from the ground up!

Resources:

Connect with and follow Caitlyn Krebs on LinkedIn.

Follow Nalu Bio on LinkedIn and visit their website!

For more information and ways to increase risk awareness and safety, visit us at⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.censinet.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Music by⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠David Cosgrove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ an accomplished composer, musician, producer, and engineer. Listen to his latest project⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Del Piombo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Learn more about your ad choices. Visit megaphone.fm/adchoices